



STATE MEDICAID DUR BOARD MEETING  
THURSDAY, February 9, 2012  
7:00 a.m. to 8:30 a.m.  
Cannon Health Building  
Room 125



## MINUTES

**Board Members Present:**

Neal Catalano, R.Ph.  
Mr. Kumar Shah  
Tony Dalpiaz, PharmD.  
Brad Hare, M.D.

Kathy Goodfellow, R.Ph.  
Joseph Miner, M.D.  
George Hamblin, R.Ph.  
Mark Balk, PharmD.

**Board Members Excused**

Peter Knudson, D.D.S.  
Joseph Yau, M.D.

Cris Cowley, M.D.

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, PharmD.  
Tim Morley, R.Ph.  
Lisa V Hunt, R.Ph.  
Bobbi Hansen, CPhT

Richard Sorenson, R.N.  
Annette Leonard, R.N.  
Merelynn Berrett, R.N.  
Heather Deering, R.N.

**Other Individuals Present:**

Gary Oderda, U of U  
Charissa Anne, J&J  
Patricia Harwood, Medimmune  
Ann Kuhns, Bristol-Meyers  
Brooks Hubbard, BIPI  
Linda Craig, Astra Zeneca  
Jeff Buel, Johnson & Johnson  
Eric Cannon, Select Health

Bryan Larson, U of U  
Kathleen Karnik, Janssen  
Corey Jones, AstraZeneca  
Mark Duddy, Genentech  
Scott Clegg, Lilly  
Russ Elbel, Select Health  
Gary Bailey, Forest

---

**Meeting conducted by: Neal Catalano, R.Ph.**

---

1. Neal Catalano opened the meeting. He turned the meeting over to Robyn Seely for Housekeeping Issues.
2. October minutes not included in meeting packet, will be reviewed at next meeting.
3. Pharmacy & Therapeutics (P&T) Committee Report: Lisa V. Hunt addressed the Board. New PDL to be published with new format, columns identifying preferred and non-preferred and a comments column for additional information. Two new classes have also been added.

4. Robyn Seely addressed the board with information about the DUR reporting requirements for Managed Care Organizations (MCO). She stated that Utah Medicaid is considering MCOs, they would be covering pharmacy coverage for clients enrolled with them. The MCOs would be required to report DUR decisions to the Medicaid DUR board for reporting to the state.

Kumar Shah asked if there are standard rules for e-prescribing, and if there are why they are not addressed with the MCOs. Robyn stated that it is not required and it is governed within the facilities that are using e-prescribing. Utah Medicaid does not require prescribers to use a specific e-prescribing company. Kumar also asked about what qualifications is Utah Medicaid looking for in DUR MCOs. Tim Morley stated that the pharmacy policy group does not have a part in selecting the MCOs, only in governing what their DUR board must report back.

5. Review of Xarelto presented by Robyn Seely. Public comment from Dr Kathy Karnik was presented to board in support of coverage of Xarelto. She stated if Xarelto is being used for continuation of care (from hospitalization) that she recommends it be covered without prior authorization. Robyn read two letters from practitioners in Utah in support of coverage of Xarelto (letters from Dr. Charles Bean and Dr. James Zebrack).

Robyn Seely suggested the board look at the cost associated with the different drug options available (price comparison sheet provided in meeting packet). She also presented a purposed prior authorization criteria sheet (included in meeting packet).

Board members requested to see price detail and breakdowns not included in the meeting packet. Robyn stated that Utah Medicaid does not have details available in the range of cost/treatment, cost/dose, cost/day, length of treatment and reason for treatment. Kathy Goodfellow stated that she checked the cost for her pharmacy to dispense Xarelto, 30 day supply of 10 mg Xarelto is most cost effective than a 10 day supply 10 mg Enoxaparin 30 mg Q12h. She recommended if there are cost advantages and easier route of administration (oral vs. injectable), then there should not be a prior authorization requirement for Xarelto.

The board discussed that it would be advantageous to cover Xarelto for non-traditional clients because they do not require a prior authorization for an oral medication. George Hamblin stated that he is in favor of elimination prior authorization requirements wherever possible to provide more timely treatment.

There was discussion to change or amend the purposed prior authorization criteria. Discussion was held to only require prior authorization for one indication and not for another. After some word rearranging and discussion including the prior authorization nurses it was determined to keep the prior authorization criteria as presented.

Joe Miner made a motion to keep the prior authorization verbiage the same as what was presented. Mark Balk seconded the motion. The motion was approved unanimously.

6. Robyn Seely presented a review of Brilinta. Public comment from Mandy Hosford was presented the board in support of coverage of Brilinta. Tim Morley asked if Brilinta is effective not in combination with Aspirin. Ms Hosford stated that Brilinta has not been studied without concurrent use of Aspirin. Robyn read a letter from Dr. James Zebrack in

support of coverage of Brilinta.

Robyn Seely suggested the board consider covering Brilinta without prior authorization.

George Hamblin made a motion that Brilinta be covered without prior authorization. Kathy Goodfellow seconded the motion. The motion was approved unanimously.

7. Bryan Larson with the University of Utah presented information about new salt formations. The University recommends placing all new salt forms on prior authorization with some exceptions:
  - The new salt form has a different route of administration than the original product.
  - The new salt form is on the Utah Medicaid Preferred Drug List.
  - The new salt form is available generically.
  - The new salt form is less costly than the original product and is projected to come off patent at the same time as or before the original product.
  - The new salt form demonstrates improved safety or efficacy in head-to-head clinical trials.

Mark Balk made a motion to accept the recommendations of the University removing the “projected to come off patent at the same time as or before the original product” requirement. Brad Hare seconded the motion. The motion was approved unanimously.

The next DUR Board meeting is scheduled for Thursday, March 8, 2011.  
The DUR Board Prior Approval Subcommittee met following the meeting.  
Minutes prepared by Bobbi Hansen.